Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of “Buy” by Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have been assigned a consensus rating of “Buy” from the eight analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have issued a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $7.40.

Several equities research analysts recently weighed in on IMUX shares. Chardan Capital raised Immunic to a “strong-buy” rating in a research note on Wednesday, November 19th. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a report on Thursday, October 16th. Roth Capital started coverage on shares of Immunic in a research note on Friday, November 7th. They issued a “buy” rating and a $3.00 price target for the company. HC Wainwright lowered their price target on shares of Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 14th. Finally, D. Boral Capital dropped their price objective on shares of Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th.

Immunic Price Performance

Shares of NASDAQ IMUX opened at $0.58 on Friday. Immunic has a 1 year low of $0.56 and a 1 year high of $1.39. The stock has a market capitalization of $69.77 million, a P/E ratio of -0.70 and a beta of 1.48. The company’s 50-day moving average is $0.74 and its 200 day moving average is $0.82.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. Research analysts anticipate that Immunic will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Qube Research & Technologies Ltd bought a new stake in Immunic in the third quarter worth $29,000. Two Sigma Investments LP purchased a new position in shares of Immunic in the 3rd quarter worth about $52,000. HB Wealth Management LLC bought a new position in Immunic in the 3rd quarter worth about $81,000. Virtu Financial LLC purchased a new stake in Immunic during the 3rd quarter valued at about $99,000. Finally, GSA Capital Partners LLP bought a new stake in Immunic during the 3rd quarter valued at about $170,000. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.